SHARE
Vitae Pharmaceuticals, NASDAQ:VTAE, VTAE

Shares of Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) ended Thursday session in green amid volatile trading. The shares closed up +0.009 points or 1.35% at $0.638 with 243,093 shares getting traded. Post opening the session at $0.68, the shares hit an intraday low of $0.62 and an intraday high of $0.68 and the price vacillated in this range throughout the day. The company has a market cap of $36.66 million and the numbers of outstanding shares have been calculated to be 57.18 million shares.

Ampio Pharmaceuticals Inc (AMPE) updated its continuing negotiations with the CBER Division of the FDA seeking the best path forward to obtain a Biological License for Ampion™ to treat patients suffering from pain caused by severe Osteoarthritis of the knee (OAK) and preliminary results from AP-011, its “hand” trial of Ampion™.

Michael Macaluso, Ampio’s CEO, noted “We are grateful to the FDA for the number of fair and reasonable paths forward to a Biological License for Ampion™ they have offered to Ampio. We hope to have a final decision on the path we will follow by year-end. As soon as we have further information, we will report the same to our shareholders.”

Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) ended Thursday session in green amid volatile trading. The shares closed up +0.73 points or 4.54% at $16.82 with 24.42 million shares getting traded. Post opening the session at $16.36, the shares hit an intraday low of $16.04 and an intraday high of $17.00 and the price vacillated in this range throughout the day. The company has a market cap of $6.14 billion and the numbers of outstanding shares have been calculated to be 347.67 million shares.

Valeant Pharmaceuticals Intl Inc (VRX) develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Xifaxan for the treatment of irritable bowel syndrome with diarrhea; Wellbutrin XL for major depressive disorder in adults; Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Clindagel, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Glumetza to improve glycemic control in adults with type 2 diabetes mellitus; PROVENGE for the treatment of prostate cancer; and Jublia for onychomycosis of the toenails.

 

 

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here